Judge accepts Paxil deal

Share this article:
An Illinois judge approved a $64-million class-action deal involving anti-depressant Paxil. The agreement, under which plaintiffs can get full refunds for their Paxil purchases, settles claims GlaxoSmithKline misled consumers by promoting the drug to children. Parties in the suit originally made the arrangement last November, contingent on a hearing to determine whether the settlement was fair and whether plaintiff’s attorneys were entitled to the $16 million settlement fee they requested. Last year the FDA issued warnings against use of Paxil in children after studies found the drug increased suicidal tendencies while having questionable effects on depression.
Share this article:

Email Newsletters

More in News

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.

Five things for pharma marketers to know: Thursday, August 21

Five things for pharma marketers to know: Thursday, ...

An Ebola survivor is set to leave Emory University Hospital, but the cause of the cure is uncertain, the FDA has approved a new type 1 diabetes test, and the ...